chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Had a severe reaction getting a Prevnar, Pneumonia vaccine 6 years ago; had high fever for 4 days; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 65-year-old patient received pneumococcal 13-val conj vac (dipht crm197 protein) (PREVNAR 13), as dose number unknown, single (Batch/Lot number: unknown) for immunisation; for immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PYREXIA (non-serious), outcome "unknown", described as "Had a severe reaction getting a Prevnar, Pneumonia vaccine 6 years ago; had high fever for 4 days".  Additional information: Consumer (patient) stated: "I am 65 and I would like to get the Prevnar pneumonia vaccine. However, I had a severe reaction getting a Prevnar, Pneumonia vaccine, 6 years ago (don't know which Prevnar). I had high fever for 4 days and I am a little concerned. I don't want to be setting myself up. My concern is, is this going to be safe? If I get that vaccine or am I likely going to get ill as I was before? ".  The information on the batch/lot number for pneumococcal 13-val conj vac (dipht crm197 protein), pneumococcal 13-val conj vac (dipht crm197 protein)  has been requested and will be submitted if and when received.
Tested positive for COVID on 7/4/2022. On 07/052022 I was seen at the clinic for coughing; nausea; fever; brain fog; abnormal nasal congestion; headache and earache which lasted a few weeks. I was seen by my PCP on 7/27/2022 for the earache and prescribed antibiotics for an ear infection. I was DX with long Covid however I was not prescribed PAXLOVID.
This spontaneous report as received from a certified medical assistant (C.M.A.) refers to an unspecified patient of unknown age and gender. On an unknown date, the patient was vaccinated with one dose of improperly stored GARDASIL 9 (lot # K026246, expiration date 28-JAN-2017, dose and route of administration were not reported). No adverse effects were reported. Product quality complaint (PQC) was not involved. Additional information has been requested.
Information has been received from a registered nurse referring to multiple unspecified patients of unknown age and gender. Concurrent condition and medical history were not reported. On multiple unspecified dates, multiple unspecified patients were administered improperly stored VARIVAX (Merck) (Lotn umber L011083, expiration date 01-APR-2017, dose, frequency and route were unknown). The patient's concomitant medication was not reported. No adverse effect reported. There was no product quality complaints (PQC) involved. This is one of several reports received from the same reporter. Additional information has been requested.
COVID; sick; arthritis flared; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID), ILLNESS (sick) and ARTHRITIS (arthritis flared) in an elderly female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 4782588) for COVID-19 vaccination.    Co-suspect product included non-company product UPADACITINIB (RINVOQ) for Rheumatoid arthritis.    Concurrent medical conditions included Rheumatoid arthritis (Moderate to Severe).   On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) 1 dosage form and UPADACITINIB (RINVOQ) (Oral) at an unspecified dose. On an unknown date, the patient experienced COVID-19 (COVID), ILLNESS (sick) and ARTHRITIS (arthritis flared). At the time of the report, COVID-19 (COVID) was resolving and ILLNESS (sick) and ARTHRITIS (arthritis flared) outcome was unknown.      No relevant concomitant medications were reported.   It was unknown if patient was enrolled in COVID-19-Vaccine Trial.  The patient had covid and was very sick got the vaccine and was very sick from it and it flared up her arthritis to being very bad colic acid along with rinvoq plans on getting flu shot but wants to find out if she should stop taking medication.  The reporter's causality for the events of arthritis flared, covid and sick with Upadacitinib was Not Provided.  No treatment information was provided.
My son is rarely sick. He came home from college, just after a few weeks from receiving the vaccine with a terrible cough and an unusual nosebleed. Every time he blows his nose, it is bloody. Never in 19 years have I observed this. My son is a college athlete and is extremely strong and healthy. These symptoms do not seem to be going away. The bloody nose is the most unusual effect and we are concerned this is an inflammatory side effect.
This spontaneous report was received from a pharmacist refers to a 79 year old female patient. Medical history reported included, high blood pressure and unspecified heart condition. The patient has not had drug reactions or allergies. On 13-MAY-2014 the patient was vaccinated with ZOSTAVAX 0.65 ml, intramuscular, lot number J013450, expiration date 24-JAN-2015. The concomitant therapies reported included COZAAR, Atenolol, PLAVIX, RESTASIS eye drops and Tretinoin cream. The reporter informed that on 13-MAY-2014, (reported as immediately) she accidentally administered ZOSTAVAX to patient, intramuscular. She stated that she monitored the patient for "30 minutes" in the pharmacy, after the ZOSTAVAX was administered intramuscular. She also stated that there was a "tiny dot" of blood at the administration site after the patient received ZOSTAVAX; she reported that the blood "went away right away". There was not laboratories performed and the patient did not received treatment for the adverse event. The patient's outcome with the event was recovered. Additional information has been requested.
About 1 hr after vaccination with rash pruritic sandpaper appearance swollen mucosa with white plaques of post pharynx.
This spontaneous report as received from a physician via a company representative refers to a 19 or 20 year old patient. On an unknown date the patient was vaccinated with one single shot of VARIVAX (dose, route and lot# not reported). On 25-AUG-2014 the patient experienced an allergic reaction and developed a red hard spot. The outcome of the patient was unknown. The patient sought unspecified medical attention. Additional information has been requested.
plaque psoriasis came back; Fever; This spontaneous case was reported by a consumer and describes the occurrence of PSORIASIS (plaque psoriasis came back) and PYREXIA (Fever) in a 44-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) for Plaque psoriasis.    No Medical History information was reported.   On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) (Subcutaneous) at an unspecified dose. On an unknown date, RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) (Subcutaneous) dosage was changed to at an unspecified dose. In 2021, the patient experienced PYREXIA (Fever). On an unknown date, the patient experienced PSORIASIS (plaque psoriasis came back). In 2021, PYREXIA (Fever) had resolved. At the time of the report, PSORIASIS (plaque psoriasis came back) had resolved.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   No concomitant medications were reported.  It was unknown if patient was enrolled in a COVID-19 vaccine trial.   Patient stopped taking Skyrizi then plaque psoriasis came back then patient started back taking Skyrizi in Nov-2021 and plaque psoriasis cleared up again.  The reporter causality for the events of fever and plaque psoriasis came back was not provided.  No treatment medications were reported.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked in.
The day of receiving my vaccine, I had some pain in my left arm. The next morning, the pain moved to my neck, to a little bit of my shoulder and the base of the skull. I went and saw a doctor. (E.N.T) and he scheduled an MRI for me. They found some degeneration due to Arthritis. I was referred to a doctor from my PCP. The doctor said this may go away and that I can take up to 2000 mg of Tylenol for the pain. I saw an Acupuncturist; doctor and it helped a bit. As of today, I am still experiencing the pain, but it is not as intense.
Severe headache; A Spontaneous report was received from a nurse concerning a 58-year-old female patient who was participating in the mRNA-1273 Emergency Use Program and developed a severe headache.   The patient's medical history, as provided by the reporter, included a knee operation and throat surgery. No relevant concomitant medications were reported.   On 02 Jan 2021, the same day as the onset of the event, the patient received their first of two planned doses of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection.   The patient experienced a severe headache beginning on 02 Jan 2021.   Action taken with mRNA-1273 in response to the event was not provided .    The event resolved on 04 Jan 2021.  No treatment information was provided.  The outcome of the event severe headache was reported as recovered on 04 Jan 2021.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded. Further information has been requested
Confusion, Dizziness, Headache, Fever, Diarrhea, NauseaVomiting,  severe muscle cramping, spasming (primary care dr prescribed Flexeril), and twitching, skin turned red. Narrative:
pt vax 23Oct97 w/ varicella live; on 26Oct97 developed approx 20 pox described as mild by MD; additional info has been requested
Headache, fever 100 F max, sore  throat, Body pain. Only took Advil.  So far, nothing serious.
03/15/2005 3:15pm Pt seen in office- raised pimple like red rash. Abdomen full, arms. Diagnosis Chicken Pox per E Kamans, MD
Patient vaccinated with Pfizer vaccine mixed with sterile water instead of 09% normal saline, preservative free. Consulted with FDA and CDC to determine next steps for patient after discovery. Re-vaccination advised. Outreach team contacted impacted patient and offered to speak with a physician to discuss.
Redness injection site and slightly swollen. Good general clinical status. Prescribed Prelone and Atarax.
Received the first dose of the Pfizer COVID-19 vaccine and tested positive for COVID-19; Received the first dose of the Pfizer COVID-19 vaccine and tested positive for COVID-19; This is a spontaneous report from a contactable consumer (patient). A female patient of an unspecified age received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Lot Number and Expiration Date were not reported), via an unspecified route of administration, on 08Apr2021, at a single dose, for COVID-19 immunization. The patient's medical history and concomitant medications were not reported.  The patient received the first dose of the Pfizer COVID-19 vaccine on 08Apr021 and next dose is due on 29Apr2021. In Apr2021, the patient tested positive for COVID-19 and wanted to know the timing of the second dose. The outcome of the events was unknown.  Information about lot number and expiration date for the suspect product will be requested in follow-up attempts.
After taking the first of 4 typhoid capsules at bedtime, my first urine the next morning appeared to contain some small amount of blood.  Urine later in the day was clear.  This has occurred after taking each of the subsequent pills.  I have not seen a doctor to confirm the presents of blood.  I called the administrator of the vaccine to report the issue but was told they had never heard of such a side effect.
Pain in left arm starting at site then spreading to shoulder and underarm. Unable to do everyday tasks or drive using arm.  Could not put arm up over head.
prolonged sz (?30min) on 3APR99; taken by amb to ER where apnea required intubation x 24hr for airway management; MRI eval showed sinusitis; tx w/ atb; NOT d/c on anticonvulsants
injected expired Moderna COVID-19 vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (injected expired Moderna COVID-19 vaccine) in a 69-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032F21A) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Feb-2022, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 23-Feb-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (injected expired Moderna COVID-19 vaccine). At the time of the report, EXPIRED PRODUCT ADMINISTERED (injected expired Moderna COVID-19 vaccine) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication of the patient was not reported.  Storage condition of the vial was refrigerated storage; maximum or minimum temperatures reached, as applicable (specify temp is in C or F): normal refrigerated temperature range 38 Fahrenheit to 40 Fahrenheit; date vial moved from freezer to refrigerator: 24-Jan-2022; currently the vial was stored in a nursing home and the reporter was not sure if the vial was discarded or the vial was still in the refrigerator. Upon visual inspection no abnormality was noted; Pertinent details: the vial was unpunctured and had no previous excursion.  No adverse event was reported.  No treatment information was provided by the reporter.   This case was linked to MOD-2022-493214 (Patient Link).
I started to experience some pains in my chest around the time that I got my vaccine. I do not know for sure exactly how long after the vaccine that it started. They symptoms came and went. I finally went to the ER. I was hospitalized for one day. They diagnosed me with pulmonary embolism. I have had follow up doctor visit with a hematologist. They ran a lot of tests and they have not been able to determine the cause of the clot(s). They ran some tests that were related to blood clotting. They all came back as inconclusive. I can't remember all of the tests that they ran. The blood clot was located in my lower right lung. I have to take blood thinners now.
This case was reported by a consumer via call center representative and described the occurrence of tremor in a 15-year-old male patient who received FLUARIX. Concurrent medical conditions included esophageal acid reflux. Concomitant products included omeprazole and Vitamin D. In October 2014, the patient received FLUARIX (intramuscular). In November 2014, 30 days after receiving FLUARIX, the patient experienced tremor (serious criteria hospitalization), nausea (serious criteria hospitalization), anxiety (serious criteria hospitalization), numbness of extremities (serious criteria hospitalization), tingling feet/hands (serious criteria hospitalization) and panic attack (serious criteria hospitalization). In January 2015, the outcome of the tremor, nausea, anxiety, numbness of extremities, tingling feet/hands and panic attack were recovered/resolved. It was unknown if the reporter considered the tremor, nausea, anxiety, numbness of extremities, tingling feet/hands and panic attack to be related to FLUARIX. Additional details were provided as follows: This case was previously reported to a doctor. This case was reported by the patient's grandmother. The reporter did not know which GSK flu vaccine the patient received. Three times between November 2014 and December 2014, the patient had a sudden onset of tremors, numbness and tingling in hands and feet, and severe nausea. He visited emergency room (ER) each time and at least once was kept under observation for 2 days. It was believed that the patient experienced panic attacks, but the reporter thought he was only anxious because he did not understand what had happened to him. The symptoms subsided between panic attacks before suddenly coming back out of the blue. The patient was fine between January 2015 to October 2015. For tolerance to vaccination received in October 2015, refer case US2016GSK020967.
36 days passed without second dose; shortness of breath; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (shortness of breath) and PRODUCT DOSE OMISSION ISSUE (36 days passed without second dose) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Mar-2021, the patient experienced DYSPNOEA (shortness of breath). On 12-Apr-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (36 days passed without second dose). At the time of the report, DYSPNOEA (shortness of breath) and PRODUCT DOSE OMISSION ISSUE (36 days passed without second dose) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, COVID-19: negative Negative.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided.A 71 year-old female patient called on 12Apr2021 to report that she received the first dose Moderna COVID-19 vaccine on 04Mar2021. Around 29Mar2021 and 30Mar2021 the patient had shortness of breath and she was advised not to take the second dose. She took covid-19 which came out negative. At the time of call 36 days has passed without second dose.
This spontaneous report as received from a licensed vocational nurse (also reported as registered nurse) refers to an unspecified number of patients of unknown age and gender. There was no information about the patients' concurrent conditions, concomitant therapies or medical histories provided. On unknown dates in 2016, starting on or after 28-APR-2016, the patients were vaccinated with improperly stored doses of VARIVAX lot # L046885, expiration date 23-NOV-2017 (dose and route of administration were not reported). There was no adverse effect reported. Administered doses of vaccines experienced the temperature excursion of 12.3 degrees Fahrenheit for 23 hours and 17 minutes. This is one of two reports received from the same reporter. Additional information has been requested.
Patient received 1st covid vaccine on 5/6/21 and 2nd dose on 5/28/21. Patient had a urgent care visit on 11/23/21 for evaluation of fever, chest pain , chest tightness and then patient presented to outside hospital ED. According to cardiology follow up note on 11/30/21, patient was diagnosed with myopericarditis 1 week prior with TnT 0.79 to 0.97, no rise and fall, CRP 144.  Patient got mri cardiac non stress imaging on 12/7/21 and the conclusion was that it was consistent with healing phase of myocarditis with normal left ventricular function. Patient was treated with ibuprofen, indomethacin and colchicine.
Information has been received from a medical assistant and a physician concerning a male who on 27-NOV-2007, 08-FEB-2008 and 30-APR-2008 was vaccinated PO with his first, second and third doses of ROTATEQ.  It was noted that the third dose was late.  The patient was not experiencing any known symptoms.  There was no product quality complaint.  No further information is available.  Additional information has been requested.
CHILLS, FEVER 103.0, CHEST RED, HEADACHES, BONE PAIN, MUSCLE ACHES
Started with abdominal pain; irregular bleeding for couple of days  and chills I went to the doctor and they put me on pro biotics and antibiotics
patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) in a 40-year-old female patient who received mRNA-1273 (Spikevax) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (unknown route) .5 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications was reported. No treatment information was reported.
Mild SOB with moderate intensity activity, similar sensation to asthma he had when he was younger.  No wheezing.  Improved after the first week.
Pain and swelling at injection site - no treatment Joint pain in hands and wrists - no treatment; occurred first thing in the morning; improved during the day.
Pain all over my body; Booster must have triggered arthritis; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non-healthcare professional) for a Pfizer sponsored program. The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown (booster), single for covid-19 immunisation. Relevant medical history included: "Throat cancer" (unspecified if ongoing), notes: I have throat cancer; "Arthritis" (unspecified if ongoing), notes: Booster must have triggered arthritis. The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary Immunization series complete; unknown manufacturer), for COVID-19 Immunization. The following information was reported: PAIN (non-serious), outcome "unknown", described as "Pain all over my body"; ARTHRITIS (non-serious), outcome "unknown", described as "Booster must have triggered arthritis". Therapeutic measures were taken as a result of pain, arthritis. Additional information: Forwarded as an Adverse Event by the team on 04Apr2022. Reporter provided verification of contact address on 01Apr2022. After receiving the covid booster, the patient began to experience pain all over the body. The patient's doctor said the booster must have triggered arthritis and prescribed celebrex for the pain. The patient only get 1600.00 dollars per month and the medicine was 111.00 per month. Patient tried to get some help from Pfizer but the patient was required to call after filling out the questions. The patient had throat cancer so the patient could not talk therefore the patient could not called.  The lot number for bnt162b2 was not provided and will be requested during follow up.
Patient reported redness at injection site with it traveling down arm. Went to Emergency room and cellulitis was confirmed. Patient will be following up with primary MD 11/11/16.